Industrial Property Act 2019

Section 23: Compulsory licence for patent

PART III: PATENTS, UTILITY MODELS, PATENT COOPERATION TREATY

Industrial Property Act 2019Section 23

23. Compulsory licence for patent (1) Subject to subsection (3), where the competent authority is satisfied that – (a) the public interest, including national security, nutrition, health or the development of other vital sectors of the national economy, so requires; (b) a judicial or administrative body has determined that the manner of exploitation, by the owner of a patent or his licensee, is anti-competitive, and that the exploitation of the invention in accordance with this subsection would remedy such practice; (c) the owner of the patent is abusively exercising his exclusive rights or neglecting to take measures to prevent his licensee from abusively exercising those rights; or (d) the invention is not available in sufficient quantities or quality or at predetermined reasonable prices in Mauritius, he may, without the consent of the owner of the patent, authorise a Government agency or a third party to exploit the patented invention. (2) (a) Subject to subsection (3), where the competent authority is satisfied that, without infringing a first patent, an application for a second patent relates to an invention which involves an important technical advancement of considerable economic significance in relation to an invention claimed in the first patent, it may, on an application from the new inventor and without the consent of the owner of the first patent, issue a compulsory licence to the inventor of the second patent on payment of the prescribed fee. (b) An application for the issue of a compulsory licence shall be accompanied by the payment of such non-refundable fee as may be prescribed. Acts 2019 503 (3) An application for a compulsory licence under subsection (2) shall be accompanied by evidence that the owner of the patent has received, from the person seeking the compulsory licence, a request for an authorisation to exploit the second patent, but that person has been unable to obtain such a licence on reasonable commercial terms and conditions and within a reasonable time which shall, unless the competent authority in exceptional circumstances otherwise determines, be 6 months from the date on which the request for authorisation to exploit the second patent was made. (4) No evidence of a request for an authorisation referred to in subsection (3) shall be required in cases of national emergency, circumstances of extreme urgency, cases of public non-commercial use or where the compulsory licence is to be granted to remedy a practice determined, after judicial or administrative process, to be anti-competitive, where the owner of the patent is, as soon as reasonably practicable, notified of the decision of the competent authority. (5) No request for a compulsory licence on the ground of insufficient availability as specified in subsection (1)(d) shall be made before the expiry of a period of – (a) 4 years from the filing date of the application for the patent; or (b) 3 years from the date of the grant of the patent, whichever period expires last. (6) A request under subsection (5) shall be refused where the owner of the patent justifies his inaction or insufficient action by legitimate reasons. (7) The owner of a patent or any interested party may make a request to be heard by the competent authority before it makes a decision under subsection (1). (8) (a) The exploitation of the invention shall be – (i) limited to the purpose for which it was licensed; and 504 Acts 2019 (ii) subject to the payment of an adequate remuneration, to be determined by the competent authority depending on the circumstances of each case, to the owner of the patent. (b) The competent authority shall, in determining the remuneration under paragraph (a)(ii), take into account – (i) the economic value of his decision; and (ii) the need to correct anti-competitive practices. (c) The competent authority shall, in determining the remuneration with respect to the compulsory licence for a patent claiming a pharmaceutical product or a process of making a pharmaceutical product, prescribe an alternative process of making the same product which is not known or is unavailable, by taking into account, where applicable, the terms and conditions of the decision of 30 August 2003. (9) The owner of a patent or holder of a compulsory licence may request the competent authority to vary the terms of the decision authorising the exploitation of the patented invention on the ground of changed circumstances after hearing the parties. (10) The owner of a patent may make a written request to the competent authority to terminate a compulsory licence. (11) Where, after hearing the parties, the competent authority is satisfied that – (a) the circumstances which led to its decision under subsection (1) have ceased to exist and are unlikely to recur; (b) the holder of a compulsory licence has failed to comply with the terms of its decision; or (c) the need for adequate protection of the legitimate interests of the holder of the licence does not justify the maintenance of its decision, he shall terminate the compulsory licence. Acts 2019 505 (12) A compulsory licence may only be transferred to – (a) the enterprise or business of the holder of the licence; or (b) the part of the enterprise or business where the patented invention is being exploited. (13) A compulsory licence shall be non-exclusive and shall not exclude – (a) the exploitation of the invention by the patent owner himself, through manufacture in Mauritius or through importation, or both; (b) the conclusion of licence contracts by the owner of the patent; and (c) the continued exercise, by the owner of the patent, of his rights under section 21(1). (14) The exploitation of an invention by the holder of a compulsory licence shall predominantly be for the supply of the market in Mauritius except where – (a) it is permitted to remedy a practice which is anti-competitive according to subsection (1)(b); (b) the compulsory licence concerns a patent claiming a pharmaceutical product or a process of making a pharmaceutical product, and the purpose of the licence is to export the patented products; (c) the products manufactured by the patented process are for a foreign territory or country with no, or with insufficient, manufacturing capacity, in accordance with the terms and conditions of the decision of 30 August 2003. (15) Where a compulsory licence is granted – (a) the owner of the first patent shall be entitled to a cross-licence, on reasonable terms, to use the invention claimed in the second patent; and 506 Acts 2019 (b) the use authorised in respect of the first patent shall be non-assignable except with the assignment of the second patent. (16) This section shall apply, where appropriate and with such modifications as may be necessary, to a pending application for a patent except in the case of insufficient availability of the patented product or of the product manufactured with the patented process.

as enacted (not consolidated). juris shows this Act from a copy that is not the official consolidation, so it may not carry every amendment; the amendments juris holds are listed. It does not confirm that this is the law in force today.

Ask juris about this section Official source